Suppr超能文献

人类乳腺肿瘤中纤溶酶原激活系统涉及的因素。

Factors involved in the plasminogen activation system in human breast tumours.

作者信息

Damjanovich L, Turzó C, Adány R

机构信息

First Department of Surgery, University School of Medicine, Debrecen, Hungary.

出版信息

Thromb Haemost. 1994 Jun;71(6):684-91.

PMID:7974332
Abstract

The plasminogen activation system is a delicately balanced assembly of enzymes which seems to have primary influence on tumour progression. The conversion of plasminogen into serine protease plasmin with fibrinolytic activity depends on the actual balance between plasminogen activators (urokinase type; u-PA and tissue type; t-PA) and their inhibitors (type 1 and 2 plasminogen activator inhibitors; PAI-1 and PAI-2). The purpose of this study was to determine the exact histological localization of all the major factors involved in plasminogen activation, and activation inhibition (plasmin system) in benign and malignant breast tumour samples. Our results show that factors of the plasmin system are present both in benign and malignant tumours. Cancer cells strongly labelled for both u-PA and t-PA, but epithelial cells of fibroadenoma samples were also stained for plasminogen activators at least as intensively as tumour cells in cancerous tissues. In fibroadenomas, all the epithelial cells were labelled for PAI-1. Staining became sporadic in malignant tumours, cells located at the periphery of tumour cell clusters regularly did not show reaction for PAI-1. In the benign tumour samples the perialveolar connective tissue stroma contained a lot of PAI-1 positive cells, showing characteristics of fibroblasts; but their number was strongly decreased in the stroma of malignant tumours. These findings indicate that the higher level of u-PA antigen, detected in malignant breast tumour samples by biochemical techniques, does not necessarily indicate increased u-PA production by tumour cells but it might be owing to the increased number of cells producing u-PA as well.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

纤溶酶原激活系统是一组精妙平衡的酶类组合,似乎对肿瘤进展具有主要影响。纤溶酶原转化为具有纤维蛋白溶解活性的丝氨酸蛋白酶纤溶酶,取决于纤溶酶原激活剂(尿激酶型;u-PA和组织型;t-PA)与其抑制剂(1型和2型纤溶酶原激活剂抑制剂;PAI-1和PAI-2)之间的实际平衡。本研究的目的是确定良性和恶性乳腺肿瘤样本中参与纤溶酶原激活及激活抑制(纤溶酶系统)的所有主要因子的确切组织学定位。我们的结果表明,纤溶酶系统的因子在良性和恶性肿瘤中均有存在。癌细胞对u-PA和t-PA均有强烈标记,但纤维腺瘤样本的上皮细胞对纤溶酶原激活剂的染色强度至少与癌组织中的肿瘤细胞一样。在纤维腺瘤中,所有上皮细胞均被标记为PAI-1。在恶性肿瘤中,染色变得散在,位于肿瘤细胞簇周边的细胞通常对PAI-1无反应。在良性肿瘤样本中,肺泡周围结缔组织基质含有大量PAI-1阳性细胞,呈现成纤维细胞特征;但其数量在恶性肿瘤基质中大幅减少。这些发现表明,通过生化技术在恶性乳腺肿瘤样本中检测到的较高水平的u-PA抗原,不一定表明肿瘤细胞产生的u-PA增加,而可能是由于产生u-PA的细胞数量增加所致。(摘要截短于250词)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验